Reuters logo
BRIEF-Immunovaccine says to initiate mid-stage trial of its blood cancer drug
May 16, 2017 / 11:16 AM / 5 months ago

BRIEF-Immunovaccine says to initiate mid-stage trial of its blood cancer drug

May 16 (Reuters) - Immunovaccine Inc

* Immunovaccine’s lead immuno-oncology candidate to enter investigator-sponsored phase 2 clinical trial in DLBCL in combination with approved anti-PD-1 drug

* Immunovaccine Inc says expects trial to begin enrolling patients following receipt of regulatory clearance from Health Canada Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below